No Data
No Data
hunan er-kang pharmaceutical (300267.SZ): the construction work of the first selected mine in Nigeria has been basically completed
Gelonghui October 11th | Hunan Er-Kang Pharmaceutical (300267.SZ) recently stated at the performance briefing that the construction of the company's first ore dressing plant investment in Nigeria is basically completed, and currently accelerating equipment debugging work, striving to produce products as soon as possible.
Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) Market Cap Increased by CN¥371m, Insiders Receive a 45% Cut
Erkang Pharmaceuticals: Semi-Annual Report 2024
Erkang Pharmaceuticals: 2024 Semi-Annual Report Summary
Hunan Er-Kang Pharmaceutical (300267.SZ) released its semi-annual performance, with a net income of 63.002 million yuan, a decrease of 87.87% year-on-year.
Hunan Er-Kang Pharmaceutical (300267.SZ) released its semi-annual report for 2024, with revenue of 6...
Hunan Er-Kang Pharmaceutical (300267.SZ): The net income in the first half of the year was 6.3002 million yuan, a year-on-year decrease of 87.87%.
hunan er-kang pharmaceutical (300267.SZ) announced its semi-annual report for the year 2024, with a reported revenue of 0.621 billion yuan, a decrease of 40.83% compared to the same period last year. The net income attributable to shareholders of the listed company was 6.3002 million yuan, a decrease of 87.87% compared to the same period last year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 2.2647 million yuan, a decrease of 90.55% compared to the same period last year. The basic earnings per share was 0.0031 yuan.
No Data
No Data